Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals.
New Jersey, June 14 2010 - Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that it has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals. Located in Pine Brook, New Jersey, the new center further strengthens the group’s in-house development capabilities.
The new facility will formulate products for production at Alvogen’s 375,000 sq. ft. commercial manufacturing site in Norwich, NY. The center is staffed with multiple teams of seasoned professionals in both formulation and analytical chemistry, all with proven track records in filing and bringing to market first-to-file ANDAs.
As Vice President of Strategic Development, Dale Martin leads Alvogen’s first-to-file product development team to pursue opportunities for the US market. Martin has over 30 years of experience in the generics industry. He began his career with Mylan Pharmaceuticals in 1977 and later worked with Abrika Pharmaceuticals (a subsidiary of Actavis Group) as VP of Corporate Development, later promoted to Managing Director of Actavis’ Florida-based product development unit, until he joined Alvogen.
Lisa Graver leads Alvogen’s IP legal strategy for the US market. A key component of her role with Alvogen is to drive first-to-file opportunities by identifying patent challenges and managing patent litigation. Prior to joining Alvogen, as Vice President of Intellectual Property, Graver spent the last eight years as an in-house attorney managing patent litigation, most recently as the VP of IP for Actavis, Inc. Before leaving private practice, she was with the IP litigation group at Kirkland & Ellis LLP.
Commenting on today’s announcement, Doug Drysdale, Chief Executive Officer of Alvogen said: ”Alvogen’s global development pipeline of more than 220 products has been built internally and through several strong strategic alliances with some of the industry’s leading companies. While we continue to grow our product pipeline through such partnerships, our expanded internal capabilities form an important cornerstone of our targeted development strategy. Alvogen has attracted a strong team to pursue first-to-file product opportunities as well as complex formulations for the US market. These first-to-file generics have the potential to be among the highest value products in our global portfolio.” Alvogen and Norwich employees celebrate an important milestone in our company’s growth.